Literature DB >> 15896483

Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism.

Diane Olin1, James MacMurray, David E Comings.   

Abstract

We examined the frequency of the T allele of the C270T polymorphism of the brain-derived nerve growth factor (BDNF) gene in a test and replication test design. Our objective was to determine if there is an association between the BDNF gene and Alzheimer's Disease (AD) in a US population. There were 106 autopsy-proven AD cases and 101 controls of similar ages in each test for a total of 212 AD cases and 202 controls. We found that there was a significant increase in the T allele in both the initial set (p=.04) and in the replication set (p=.018). For both groups combined p=.0008. Odds ratio=3.28, 95% CI=1.69-6.34. There were 54 cases of early-onset AD (EOAD) and 159 cases of late-onset AD (LOAD). The results were only significant for LOAD, p=.0002, odds ratio=3.81, 95% CI=1.93-7.52. The r2 or fraction of the variance attributed to the BDNF gene for the LOAD cases was .046. The results were independent of the APOE epsilon4 allele. When the younger controls were removed, providing a close age match to the AD subjects, the frequency of the T allele was even lower and the differences were still significant for both total AD and LOAD cases. In a logistic regression analysis including APOE, age, sex and BDNF, BDNF was significant at p<.0001. We concluded that BDNF gene variants are significant risk factors for late onset AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896483     DOI: 10.1016/j.neulet.2005.02.017

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

1.  Sex Differences in Risk for Alzheimer's Disease Related to Neurotrophin Gene Polymorphisms: The Cache County Memory Study.

Authors:  Joshua Matyi; JoAnn T Tschanz; Gail B Rattinger; Chelsea Sanders; Elizabeth K Vernon; Chris Corcoran; John S K Kauwe; Mona Buhusi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-11-09       Impact factor: 6.053

2.  Associations Between ApoEε4 Carrier Status and Serum BDNF Levels--New Insights into the Molecular Mechanism of ApoEε4 Actions in Alzheimer's Disease.

Authors:  Yu-Hui Liu; Shu-Sheng Jiao; Ye-Ran Wang; Xian-Le Bu; Xiu-Qing Yao; Yang Xiang; Qing-Hua Wang; Lin Wang; Juan Deng; Jing Li; Xin-Fu Zhou; Hua-Dong Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-07-02       Impact factor: 5.590

3.  BDNF inhibits neurodegenerative disease-associated asparaginyl endopeptidase activity via phosphorylation by AKT.

Authors:  Zhi-Hao Wang; Wanqiang Wu; Seong Su Kang; Xia Liu; Zhiping Wu; Junmin Peng; Shan Ping Yu; Fredric P Manfredsson; Ivette M Sandoval; Xuebo Liu; Jian-Zhi Wang; Keqiang Ye
Journal:  JCI Insight       Date:  2018-08-23

4.  MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer's disease.

Authors:  Ning Tian; Zeyuan Cao; Yan Zhang
Journal:  Neurosci Bull       Date:  2014-03-06       Impact factor: 5.203

Review 5.  Back to the future with phenotypic screening.

Authors:  Marguerite Prior; Chandramouli Chiruta; Antonio Currais; Josh Goldberg; Justin Ramsey; Richard Dargusch; Pamela A Maher; David Schubert
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

6.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

Review 7.  Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer's Disease.

Authors:  Lucia Caffino; Francesca Mottarlini; Fabio Fumagalli
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

Review 8.  Brain-derived neurotrophic factor in neurodegenerative diseases.

Authors:  Chiara Zuccato; Elena Cattaneo
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

9.  Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.

Authors:  Andrew R Schneider; Youssef Sari
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

10.  BDNF variants, premorbid educational attainment, and disease characteristics in Alzheimer's disease: an exploratory study.

Authors:  Kristina F Zdanys; Timothy G Kleiman; Huiping Zhang; Fatih Ozbay; Martha G MacAvoy; Joel Gelernter; Christopher H van Dyck
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.